Regional Oncology Center, Agadir, Morocco.
Mohammed VI Cancer Treatment Center, Radiation-Oncology Department, Ibn Rochd University Hospital, Casablanca, Morocco.
Gulf J Oncolog. 2021 Jan;1(35):82-85.
Large-cell neuroendocrine carcinoma (LCNEC) of the ovary is rare, highly aggressive tumor and diagnosed at advanced stages. Immunohistochemistry is required for the diagnosis. The optimal treatment management is not codified because of its rarity.
We report the case of a 36-year-old woman with a locally advanced stage LCNEC of the ovary managed by surgery and adjuvant chemotherapy with etoposide and cisplatin. She remained disease free until now four years after the end of chemotherapy.
This report suggests the necessity of immunohistochemical analysis in the diagnosis of LCNEC of the ovary. Due to the rarity of LCNC, the general consensus on treatment is not standardized. We used adjuvant chemotherapy regimen similar to large cell carcinoma of the lung.
卵巢大细胞神经内分泌癌（LCNEC）是一种罕见的、高度侵袭性肿瘤，通常在晚期诊断。诊断需要进行免疫组织化学检测。由于其罕见性，目前尚未规范最佳的治疗管理方法。
我们报告了一例 36 岁的局部晚期卵巢大细胞神经内分泌癌患者，采用手术和依托泊苷联合顺铂辅助化疗进行治疗。患者在完成化疗后至今四年内无疾病进展。
本报告提示在诊断卵巢大细胞神经内分泌癌时需要进行免疫组织化学分析。由于 LCNEC 非常罕见，因此对于治疗的普遍共识尚未标准化。我们使用的辅助化疗方案与肺大细胞癌相似。
